New Statistical and Machine Learning Methods for Cancer Research: Technologies for Adaptive Trials, Precision Therapies and Drug Development
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".
Deadline for manuscript submissions: closed (25 February 2025) | Viewed by 751
Special Issue Editor
Special Issue Information
Dear Colleagues,
Electronic health records are becoming commonplace in cancer care, and this has led to readily available databanks for advanced research. In this context, a multitude of new approaches in the domains of statistical and machine learning are being developed to analyze these cancer-related databases, to gain new insights, and to guide the development of new trials with novel statistical design mechanisms. Computational techniques associated with analyzing cancer research data are an important and impactful research area, especially with a focus on disease prediction/prognosis, cancer-related adaptive trials, and new drug development. In this Special Issue, we invite papers that deal with technologies and methods in this domain, with the following focus areas:
- Novel statistical methods that are empirically robust and broadly applicable for new drug development and disease delineation/prognosis/prediction in cancer.
- Association studies, for example, studies targeting “omics” profiling for new personalized cancer therapies and related novel machine and statistical methods specifically tailored for “omics” research in cancer.
- New statistical designs for adaptive clinical trials in cancer research.
Dr. Anjishnu Banerjee
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- statistical methods
- machine learning
- “Omics” research
- adaptive clinical trials
- drug development
- personalized cancer therapies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
